STOCK TITAN
  1. Home
  2. News
  3. MSCLF
  4. Satellos Announces Participation in September 2024 Investor Conferences

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), a biotech company developing new small molecule therapeutics for muscle diseases, has announced its participation in two upcoming investor conferences in New York City.

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Tags
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Mr. Frank Gleeson, Co-founder and CEO of Satellos will participate in fireside chats and one-on-one meetings during the following conferences taking place in New York City along with Ms. Elizabeth Williams, CFO of Satellos.

H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat
Date: Wednesday, September 11th at 8:00 a.m. ET

Cantor 2024 Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 19th at 9:45 a.m. ET

The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the presentations.

About Satellos Bioscience Inc.

Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com.

Investors: Liz Williams, ir@satellos.com
Business Development: Ryan Mitchell, Ph.D., bd@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091

Source: Satellos Bioscience Inc.

Keep reading

More on MSCLF

All MSCLF news

Trending in the feed

GUTS
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation Open the live feed
View all latest news